N,α-Diethylphenethylamine
chemical compound
N,α-Diethylphenethylamine (DEPEA or NADEP), also known as 2-ethylamino-1-phenylbutane (EAPB) is a stimulant drug of the phenylisobutylamine (α-ethylphenethylamine) group. It is a close chemical analog of methamphetamine, which has been sold as a designer drug. It was originally patented by Knoll Pharma as one of several analogs for pharmaceutical applications. In animal models these analogs showed properties of cognitive enhancement and increased pain tolerance. Nevertheless, this class of compounds was never developed into a medicine.
Pharmacology
DEPEA is a mixed norepinephrine–dopamine releasing agent (NDRA) and norepinephrine–dopamine reuptake inhibitor (NDRI). It is a full releaser of norepinephrine but a weak partial releaser of dopamine with a maximal efficacy of about 40% in rat brain synaptosomes. In another study however, DEPEA non-significantly released norepinephrine but did not release dopamine at all in human embryonic kidney 293 (HEK293) cells transfected with the monoamine transporters, whereas it continued to act as an NDRI in this system. In a third study, DEPEA did not induce dopamine efflux in rat striatal slices. The drug produces hyperlocomotion, a stimulant-like effect, in rodents.
Begin with the source’s own compact description: “N,α-Diethylphenethylamine” is chemical compound. The dossier treats that line as a proposition to test through α-Diethylphenethylamine, chemical and compound, not as a finished interpretation.
Why this record matters
The phrase “chemical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Feb 3, 2025. The linked authority identifier is Q16634226. None of the 0 selected statements returned an explicit reference.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “N,α-Diethylphenethylamine”, its source revision and the description used here.
- Expand the search: follow N,α-Diethylphenethylamine primary sources, N,α-Diethylphenethylamine archive and α-Diethylphenethylamine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “N,α-Diethylphenethylamine”?
- Which observation, specimen, dataset or publication supports the account?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “N,α-Diethylphenethylamine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.